Status:
COMPLETED
Flumazenil Reversal of Oral Triazolam
Lead Sponsor:
University of Washington
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Dental Anxiety
Eligibility:
All Genders
18-40 years
Phase:
PHASE1
PHASE2
Brief Summary
An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacolog...
Eligibility Criteria
Inclusion
- ASA I
Exclusion
- Use of benzodiazepines, anxiolytics or any other medications that would interact with either triazolam's or flumazenil's metabolism or clinical effect (including herbals) within four weeks of the study
- Body mass index (BMI) no less than 15 kg/m2 and no greater than 30 kg/m2
- Pregnancy or not currently using pharmacologic methods of birth control
- Allergy or sensitivity to benzodiazepines
- History of a seizure disorder; AND
- Chronic tobacco use.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00695630
Start Date
September 1 2006
End Date
December 1 2007
Last Update
June 12 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dental Fears Research Clinic
Seattle, Washington, United States, 98195